Enliven Therapeutics, Inc. announced that it has entered into a securities purchase agreement to issue 5,357,144 shares at a price of $14 per share for the gross proceeds of $75,000,016 and pre funded warrants at a price of $13.999 per warrant for the total gross proceeds of $90,000,000 on March 19, 2024. The Pre-Funded Warrants will be exercisable into 1,071,505 shares and will have an exercise price of $0.001 per share of common stock.